MRNA sinks as positive Phase III cancer data fails to impress
FROM THE WIRE · FINANCE.YAHOO.COM
Moderna MRNA, along with partner Merck MRK, reported detailed positive results from the phase III INTerpath-001 study evaluating their investigational personalized cancer therapy in certain patients with high-risk melanoma, a serious form of skin cancer. The study evaluated…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishPhase III clinical data from Moderna and Merck with a negative reaction in Moderna's stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Moderna and Merck reported detailed results from the Phase III INTerpath-001 study.
- 02The study evaluates the personalized therapy combined with Keytruda in high-risk melanoma.
- 03Top-line results announced in August 2026 had already met the primary endpoint of recurrence-free survival.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Moderna, Inc.203.20 USD-1.00%today +0.28%Negative Merck & Co., Inc.144.90 USD+0.37%today -1.59%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets